Jan 21st 2013 - Edison Investment Research today published a report on Neovacs entitled "Crohn’s Trials Are Still On". In summary, the report says:
Despite disappointing interim Phase II trial results in Crohn’s disease (CD) in June, recent final results from the same trial demonstrated an encouraging association between the TNFα-Kinoid induced antibody titres and clinical remission. These supportive results would appear to confirm the hypothesis that the original study design was flawed, which led to disappointing results. This, together with promising new Phase II data in rheumatoid arthritis (RA) at six months, supports the continued development of the TNFα-Kinoid in both CD and RA. The next step for the TNFα-Kinoid is a Phase IIb/III study. Neovacs is also developing an IFNα-Kinoid for lupus, which is ready to move into a Phase IIb study, pending a financing or partnership.
Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »